Is lumateperone (Caplyta®) really different from other atypical antipsychotics?

Lumateperone (US brand name Caplyta®) is a second-generation (“atypical”) antipsychotic that was approved by the US FDA in 2019. For basic information about this medication, please see the following article on this website: Lumateperone (Caplyta®): Basic information Estimated cost As of June 2022, 30 capsules (a one-month supply) of lumateperone 42 mg cost about $1500…